Fat metabolism may be disturbed in conditions such as renal insufficiency, uncompensated diabetes, pancreatitis, certain forms of liver insufficiency, metabolic disorders and sepsis. If intravenous fat is considered to be indicated in the abovementioned disorders, elimination of fat should be checked daily. In cases of verified or suspected liver insufficiency, liver condition and function must be closely followed. Formulation contains soya oil and egg lecithin which may rarely cause allergic reactions. Cross-allergic reaction observed between soya-bean and peanut. Soybean oil should be given with caution to neonates and premature infants with hyperbilirubinemia and in cases with suspected pulmonary hypertension. In low birthweight infants, the risk of lipid infusions may outweigh potential benefits due to further diminution of defenses against infection. In infants, metabolism of lipids in peripheral tissues may be diminished by infection and heparin administration. In neonates receiving long-term parenteral nutrition, particularly premature neonates, platelet count, liver function tests and serum triglyceride concentration should be monitored. Soybean oil may interfere with certain laboratory measurements (bilirubin, lactate dehydrogenase, oxysaturation, hemoglobin), if blood is sampled before fat has been adequately cleared from the bloodstream. Fat is cleared after a fat-free interval of 5-6 hours in most patients.